Seeing Is Believing
Currently out of the existing stock ratings of Reni Benjamin, 170 are a BUY (85.86%), 27 are a HOLD (13.64%), 1 are a SELL (0.51%).
Analyst Reni Benjamin, currently employed at JMP, carries an average stock price target met ratio of 40.85% that have a potential upside of 50.02% achieved within 173 days.
Reni Benjamin’s has documented 366 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on INBX, Inhibrx at 15-May-2025.
Analyst best performing recommendations are on CTIC (CTI BIOPHARMA CORP).
The best stock recommendation documented was for CTIC (CTI BIOPHARMA CORP) at 3/2/2022. The price target of $5 was fulfilled within 23 days with a profit of $1.63 (48.37%) receiving and performance score of 21.03.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$17
$8.9 (109.88%)
$40
17 days ago
(06-May-2025)
0/6 (0%)
$9.6 (129.73%)
Hold
$14
$5.9 (72.84%)
$17
21 days ago
(02-May-2025)
1/9 (11.11%)
$4.7 (50.54%)
12
Buy
$22
$13.9 (171.60%)
$26
21 days ago
(02-May-2025)
1/12 (8.33%)
$12.7 (136.56%)
174
Buy
$29
$20.9 (258.02%)
$30
21 days ago
(02-May-2025)
0/21 (0%)
$19.7 (211.83%)
Buy
$32
$23.9 (295.06%)
$35
21 days ago
(02-May-2025)
0/3 (0%)
$22.7 (244.09%)
Which stock is Reni Benjamin is most bullish on?
Which stock is Reni Benjamin is most reserved on?
What Year was the first public recommendation made by Reni Benjamin?